A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic
1Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
2Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran
3Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States
4Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
5Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran
7Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
8Behavioral Science Institute, Radboud University, Nijmegen, Netherlands
9School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
10Surrey and Borders Partnership National Health Service Foundation Trust, Leatherhead, United Kingdom
11Turning Point, Eastern Health, Box Hill, VIC, Australia
12Departments of Anthropology and Psychiatry, New York University, New York, NY, United States
13Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States
14Yale School of Medicine, Connecticut Council on Problem Gambling and Connecticut Mental Health Center, New Haven, CT, United States
15Division of Population and Behavior Sciences, Medical School, University of St Andrews, St Andrews, United Kingdom
16Laureate Institute for Brain Research, Tulsa, OK, United States
*Correspondence: Hamed Ekhtiari hekhtiari@laureateinstitute.orgAbstract
Background and Aims: COVID-19 has infected more than 77 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing, and “lockdown” measures have affected drug and alcohol supply chains and subsequently their availability, price, and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic.
Design: Cross-sectional survey.
Setting: Worldwide.
Participants: Starting on April 4, 2020 during a 5-week period, the survey received 185 responses from 77 countries.
Measurements: To assess addiction medicine professionals' perceived changes in drug and alcohol supply, price, use pattern, and related complications during the COVID-19 pandemic.
Findings: Participants reported (among who answered “decreased” or “increased”) a decrease in drug supply (69.0%) and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported, while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall.
Conclusions: The global report on changes in the availability, use patterns, and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to people with SUD.
Introduction
As of December 23, 2020, the COVID-19 pandemic has around 77 million cases of infection in more than 200 countries with above 1,711,000 overall deaths (1). Approximately 6 months after cases were first diagnosed, there remain few reliable treatments and no vaccines available, and an increasing number of countries are experiencing dangerous COVID-19 transmission (2, 3). Among vulnerable populations to infection and its complications are people with substance use disorders (SUDs) (4). Both comorbid medical conditions in SUDs (such as cardiopulmonary diseases and related risk factors) and drug–drug interactions (between COVID-19 medications and abused substances or SUD treatment medications), along with other factors, may lead to people with SUDs experiencing more complications when encountering COVID-19 infections (4–6).
People with SUDs are vulnerable given marginalization, stigmatization, and poor access to health and social services (7, 8). According to risky behaviors and disadvantaged environments associated with SUDs, people with SUD may not only bear additional risks for COVID-19 but also experience poorer outcomes (4). Therefore, during the pandemic, gathering current information on the status of SUD is critical to support planning and mobilizing timely responses to minimize risks (4). Alterations in alcohol and drug supplies may change prices and availability and therefore use patterns. The COVID-19 pandemic has resulted in quarantines, travel bans, regulatory changes, and social distancing “lockdown” measures globally, with impacts on supply chains. In the setting of COVID-19-related stressors, there may be decreases in drug and alcohol availability, increases in price and use patterns, and possible downstream effects on SUD presentations and treatment demands. Such changes could directly/indirectly affect people with SUDs and give rise to new challenges and additional needs in the field of addiction medicine. Drug shortages, as the United Nation Office for Drug and Crime (UNODC) reports, could have negative health consequences regarding transitioning to consumption of harmful domestically produced substances along with more dangerous patterns of drug use including shifting to injections and using shared drug administration equipment, especially in the case of heroin (9). Additionally, the lack of drug supply may result in higher prices for some substances and bring financial burden to drug users and increase the odds of risky/illegal behaviors (4). Concurrently, as legal liquor shops may remain closed during the lockdown in some countries, multiple problems may occur ranging from alcohol withdrawal to toxicity and death due to shifting to low-quality homemade liquor and accidental methanol ingestion (4, 10).
People with SUDs could be exposed to some indirect risks during the COVID-19 era as well (5). For instance, as healthcare facilities become more difficult to access during lockdowns, people with SUDs may experience more difficulties relating to poor access to treatment centers. Socioeconomically disadvantaged backgrounds and diminished availability of public transportation may exacerbate such concerns (4, 5, 11), especially for individuals receiving daily prescriptions of opioid substitution therapy (4). Professional authorities and health policymakers are expected to proactively address such emerging needs. However, the lack of reliable data complicates the generation and implementation of evidence-based policies.
Although some activities and reports from different worldwide organizations have initially responded to the COVID-19 pandemic, data provided have been limited and, in some occasions, as UNODC has reported, the information base for analyses has been restricted and feasibility of implementation unknown1 (12– 16). Thus, a vacancy exists for a comprehensive report describing the global situation with respect to drug use, drug supply, and related complications.
In order to formulate a comprehensive health response, it is important to understand alcohol and drug markets' situation (availability and price), use patterns and related complications, and how they may have changed during the pandemic. Designing a global in-depth epidemiologic study, apart from questions about its feasibility, is challenging during the pandemic. Therefore, the International Society of Addiction Medicine (ISAM) designed a comprehensive global survey and collected expert opinions on perceived changes in substance use situation and health system responses around the 1st week of April 2020 in what aims to be a longitudinal study (17).
Here, we report results from the first round of the ISAM global survey on drug and alcohol use, price, supply, and complications during the COVID-19 pandemic. Data related to the second section of the survey concerning substance use treatment and harm reduction services responses to the pandemic have been published recently (18). We hypothesized that drug and alcohol use would increase, prices would increase, supply would decrease, and complications would increase and that results would differ by region (given the differential spread of COVID-19 and regional responses to the COVID-19 pandemic). We hope that current data will help to address the urgent need for more accurate information about the status of drug and alcohol use in the current pandemic and provide information about appropriate modifications in health system services to respond to the emerging demands in the current pandemic and similar potential pandemics in the future.
Methods
Sample
The complete study protocol has been previously published (17). The ISAM mailing list (and subsequent snowballing methodologies) comprising addiction medicine professionals across the world were contacted on April 4, 2020 by email with an invitation to participate in the study by clicking on a link to the online survey. The invitees were informed that the survey will ask about their opinions and information toward COVID-19 pandemic impact on SUDs. They also initially consented to be included as an author in the publications following the survey. Those who approved the manuscript and authorship were included among the main authors or the ISAM Global Survey Consortium (ISAM-GSC) based on their contribution in this project. Data collection was concluded on May 8, 2020.
Questionnaire
The questionnaire consisted of 92 questions in two main sections: (1) situational assessment during the pandemic and (2) health response to the pandemic. This paper provides an analysis of data obtained from the situation assessment section of the survey concerning changes in drug use, supply, price, risky behaviors, as well as related measures, namely morbidities, mortalities, and overdose rates during the COVID-19 pandemic period in different countries (17). Questions on the situational assessment section of the survey are available in Supplementary Method 2. The questionnaire was distributed in English for all the respondents.
Statistical Analysis
All statistical analyses were conducted using RStudio (v. 1.2.1335). Descriptive data are presented as means and percentages for each country's response, as well as the average of the global responses.
Ethics Approval
The survey protocols and all materials, including the survey questionnaires, received approval from the University of Social Welfare and Rehabilitation Sciences', ethics committee in Tehran, Iran (Code: IR.USWR.REC.1399.061).
Results
Respondents' Global Distribution
Overall, 185 respondents from 77 countries participated. Eight responses were excluded because of insufficient information provided (the “insufficient information” was predetermined as having more than 50% of “I do not know” responses). Data from the rest of the 177 respondents were analyzed. The list of the countries that provided information for this survey is available as a supplement (Supplementary Method 1). Figure 1 depicts a map of the respondents' global distribution.
Respondents' Demographic Characteristics
Respondents consisted of 111 males (62.7%), 62 females (35%), and 4 people (2.3%) who selected “other” or preferred not to disclose their gender. The mean age of the respondents was 46.51 ± 10.78 years. Most respondents were medical professionals (MDs) (n = 148, 83.6%), and the most frequent primary discipline was psychiatry (n = 95, 53.7%). Information related to the respondents' main disciplines and academic degrees is shown (Table 1).
| N/Mean (± SD) | Percent (%) | ||
|---|---|---|---|
| Gender | |||
| Male | 111 | 62.7 | |
| Female | 62 | 35 | |
| Other/not disclosed | 4 | 2.3 | |
| Age in years | 46.51 (± 10.78) | ||
| Academic qualification/s | |||
| BSc | 6 | 3.4 | |
| MSc | 13 | 7.3 | |
| MD | 72 | 40.7 | |
| MD; MSc | 13 | 7.3 | |
| MD; PhD | 32 | 18.1 | |
| PhD | 31 | 17.5 | |
| Others | 10 | 5.6 | |
| Primary professional discipline | |||
| Addiction medicine | 19 | 10.7 | |
| Drug/health policy | 8 | 4.5 | |
| General medicine | 17 | 9.6 | |
| Pharmacology | 2 | 1.1 | |
| Psychiatry | 95 | 53.7 | |
| Psychology/counseling | 20 | 11.3 | |
| Social work | 5 | 2.8 | |
| Other medical specialties | 3 | 1.7 | |
| Others | 8 | 4.5 | |
Drug use During Pandemic
Respondents provided information about drug use changes in their countries during the COVID-19 pandemic. Over 63% (n = 49), 42% (n = 32), 64% (n = 50), and 41% (n = 32) of the countries reported that use of alcohol, cannabis, sedatives, and prescription opioids increased, respectively. Conversely, opiates, amphetamine, and cocaine use has seen a decrement in 31% (n = 24), 29% (n = 22), and 29% (n = 23) of the countries, respectively. Perceived drug use changes by country are shown (Figure 2, Table 2). Details of drug use changes are reported in Supplementary Material.
| Responders (177) | Countries (77) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decrease | No change | Increase | Others | Decrease | No change | Increase | Others | |||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
| Use | ||||||||||||||||
| Alcohol | 43 | 24% | 13 | 7% | 109 | 62% | 12 | 7% | 19 | 25% | 6 | 8% | 49 | 63% | 3 | 4% |
| Cannabis | 44 | 25% | 35 | 20% | 75 | 42% | 23 | 13% | 20 | 26% | 17 | 22% | 32 | 42% | 8 | 10% |
| Opiates | 53 | 30% | 43 | 24% | 38 | 21% | 43 | 24% | 24 | 31% | 16 | 20% | 14 | 18% | 23 | 30% |
| Amphetamines | 49 | 28% | 30 | 17% | 33 | 19% | 65 | 37% | 22 | 29% | 15 | 20% | 14 | 18% | 26 | 33% |
| Cocaine | 52 | 29% | 28 | 16% | 25 | 14% | 72 | 41% | 23 | 29% | 15 | 19% | 10 | 14% | 29 | 38% |
| Sedatives | 19 | 11% | 24 | 14% | 105 | 59% | 29 | 16% | 5 | 6% | 9 | 11% | 50 | 64% | 14 | 18% |
| Presc. Opioids | 27 | 15% | 35 | 20% | 66 | 37% | 49 | 28% | 8 | 11% | 16 | 21% | 32 | 41% | 21 | 27% |
| Supply | ||||||||||||||||
| Alcohol | 62 | 35% | 49 | 28% | 52 | 29% | 14 | 8% | 26 | 34% | 21 | 28% | 24 | 31% | 6 | 7% |
| Cannabis | 62 | 35% | 46 | 26% | 33 | 19% | 36 | 20% | 29 | 37% | 18 | 24% | 15 | 20% | 15 | 19% |
| Opiates | 71 | 40% | 34 | 19% | 18 | 10% | 54 | 31% | 31 | 41% | 14 | 18% | 6 | 8% | 26 | 33% |
| Amphetamines | 54 | 31% | 34 | 19% | 19 | 11% | 70 | 40% | 29 | 38% | 14 | 18% | 7 | 9% | 27 | 35% |
| Cocaine | 56 | 32% | 32 | 18% | 15 | 8% | 74 | 42% | 26 | 34% | 14 | 18% | 7 | 9% | 30 | 39% |
| Price | ||||||||||||||||
| Alcohol | 5 | 3% | 91 | 51% | 57 | 32% | 24 | 14% | 3 | 4% | 42 | 54% | 23 | 29% | 10 | 13% |
| Cannabis | 4 | 2% | 51 | 29% | 70 | 40% | 52 | 29% | 2 | 3% | 23 | 30% | 30 | 39% | 22 | 28% |
| Opiates | 2 | 1% | 33 | 19% | 75 | 42% | 67 | 38% | 2 | 2% | 14 | 18% | 29 | 37% | 33 | 43% |
| Amphetamines | 3 | 2% | 33 | 19% | 57 | 32% | 84 | 47% | 2 | 3% | 13 | 17% | 26 | 34% | 35 | 46% |
| Cocaine | 1 | 1% | 35 | 20% | 51 | 29% | 90 | 51% | 0 | 0% | 18 | 23% | 21 | 28% | 37 | 49% |
| Morbidity and mortality | ||||||||||||||||
| Alcohol | 7 | 4% | 34 | 19% | 72 | 41% | 64 | 36% | 5 | 7% | 16 | 21% | 27 | 35% | 29 | 38% |
| Drug | 7 | 4% | 34 | 19% | 68 | 38% | 68 | 38% | 5 | 6% | 14 | 18% | 28 | 36% | 30 | 39% |
| Overdose | 14 | 8% | 53 | 30% | 35 | 20% | 75 | 42% | 7 | 9% | 24 | 32% | 14 | 18% | 32 | 42% |
Respondents were also asked to report changes in behavioral addictions (gaming/gambling) in their countries through the following options: Increased, Decreased, No change, I do not know; 85.7% (n = 66) of the countries reported that behavioral addictions rates had increased, whereas 14% (n = 11) of the countries reported that behavioral addictions rates had decreased in their countries during the COVID-19 pandemic (Supplementary Figure 1).
Drug Supply
Respondents provided information about perceived drug supply changes in their countries during the COVID-19 pandemic. The drug categories included the following: alcoholic beverages, cannabis (including marijuana and synthetic cannabinoids such as spice, K2, etc.), opiates (including opium, heroin, opium residue, etc.), amphetamine-type stimulants (including amphetamine, methamphetamine, MDMA, etc.), and cocaine (including crack cocaine).
Decreased supply patterns for all substances were noted. A decrement was reported in supply in 34% (n = 26) of the countries for alcohol, 37% (n = 29) for cannabis, 41% (n = 31) for opiates, 38% (n = 29) for amphetamines, and 24% (n = 26) for cocaine (Figure 3, Table 2). Details of drug supply changes are reported in the Supplementary Material.
Drug Price
Respondents provided information regarding perceived drug price changes in their countries during the COVID-19 pandemic. The price of cannabis, opiates, amphetamines, and cocaine increased in 39% (n = 30), 37% (n = 29), 34% (n = 26), and 28% (n = 21) of the countries, respectively. Alcohol price was reported as unchanged in 54% (n = 42) of the countries (Figure 4, Table 2). Details of drug price changes are reported in the Supplementary Material.
The information related to changes in drug price among different countries is shown in Figure 4 and Table 2.
Perceived Morbidity and Mortality (Including Overdose)
Respondents provided information about whether morbidity and mortality, including fatal and non-fatal overdose rates, in their countries had changed during the COVID-19 pandemic. Mortality rates in people with alcohol use disorders (AUDs) and SUDs were reported to have increased in 35% (n = 27) and 36% (n = 28) of the countries, respectively. No changes in fatal and non-fatal overdose rates were reported by 32% (n = 24) of the countries (Figure 5, Table 2). Details of changes in mortalities and overdose rates are reported in the Supplementary Material.
Risky Behaviors
Respondents provided information about changes in risky behaviors among people with SUDs in their countries during the COVID-19 pandemic (Figure 6, Supplementary Table 1). Information related to risky behaviors consisted of increased/switching to injection, sharing drug use equipment, needle and syringe sharing, and risky sexual behaviors. Sixteen percent (n = 29) of the respondents reported that injection among people with SUDs has increased, while 33% (n = 58) reported no change in numbers of people injecting drugs or people switching to injection. Fifty-one percent (n = 90) chose the “others” option indicating a lack of information or reluctance in responding to this question. Twenty-three percent (n = 41) of the respondents reported that sharing drug use equipment (i.e., paraphernalia) has increased, while 25% (n = 44) reported no change. Fifty-two percent (n = 92) chose the “others” option indicating a lack of information or reluctance in responding. Twenty-one percent (n = 38) reported that sharing needle and syringe has increased, while 24% (n = 43) reported no change. Fifty-four percent (n = 96) chose the “others” option indicating a lack of information or reluctance in responding to this question. Twenty-three percent (n = 41) reported that risky sexual behaviors have increased, while 22% (n = 39) reported no change. Fifty-five percent (n = 97) chose the “others” option. Respondents reported an increase in behavioral addictions during the pandemic (Supplementary Figure 1).
COVID-19 Overall Impact on SUDs
Respondents provided an overall rating of the general impact of the COVID-19 pandemic on people with SUDs in their countries (Figure 7). Respondents from Oman, Kenya, and Georgia rated the highest severity of COVID-19 impact on people with SUDs in their countries (ratings of 10/10), while respondents from Botswana and Afghanistan rated the lowest severity for this impact in their countries (ratings of 2/10).
Discussion
According to the results of this first-ever COVID-19 and SUD global survey with the contribution of 177 addiction medicine professionals/policymakers from 77 countries, the majority of respondents believed that in their countries, people with SUDs had been seriously affected by the COVID-19 outbreak. They mostly believed that prices for alcohol and drugs have risen, and they have become less available during the pandemic. In regard with alterations in use patterns, respondents perceived an increase the use of alcohol, cannabis, prescribed opioids, and sedative/hypnotics, and a decrease in the use of amphetamines, cocaine, and opiates. Most respondents reported increases in complications related to drug and alcohol use including increased morbidity and mortality in people with SUDs.
Alterations in levels of alcohol consumption during pandemic are similar to those reported during prior social crises, like the 2008–2009 economic downturn (19). Changes in alcohol consumption may arise from two potentially contradictory, however interacting mechanisms: (1) a problematic increase, usually stemming from distress that is being experienced especially at the beginning of a crisis, or in an attempt to “stockpile”; or (2) a decrease due to the lack of access and financial difficulties, which may lead to withdrawal (20). Current reports from Australia indicate increases in purchases of alcoholic beverages during lockdown potentially due to the first mechanism (21). However, India seems to be encountering a surge in numbers of individuals withdrawing from alcohol (5, 22). These independent reports from Australia and India are in line with our survey findings (Figure 2). Initial reports from Australia and the United States indicate overall increases in alcohol sales, especially in online alcohol delivery subsectors (21), although specific data from the industry on alcohol supply are largely lacking. However, there was no consensus among our survey respondents about changes in alcohol supply, as the responses that reported an increase, decrease, and no change were approximately equal. Approximately half of our survey respondents believed that there is no change in alcohol cost during the pandemic. This is while almost another half reported an increase in alcohol prices. We could not find any relevant reports indicating alcohol price alterations. Further data are needed as the pandemic progresses and hopefully resolves.
There are currently concerns about morbidity and mortality spikes within people with AUDs and alcohol-associated liver disease during the pandemic (23). The survey's results support the idea that these spikes can be seen among people with AUDs. Reports from Iran describe methanol poisoning of around 5,000 people with nearly 700 deaths, which may be due to lack of education and illegal and uncontrolled alcohol sales because of alcohol bans in Iran (10, 24, 25). However, to the best of our knowledge, there are yet no specific reports demonstrating the extent of alcohol overdose. The same pattern also applies to drug-related mortalities and morbidities.
Survey results suggest increases in cannabis use in more than half of participating countries. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has investigated this matter through three large darknet markets (26) in the first 3 months of 2020 and reported overall increased market activity, mostly in relation to cannabis products (13, 27). This might show the initial effects of the pandemic on the European countries market, particularly before peaks in the number of people infected by COVID-19 and subsequent widespread lockdowns.
Opiates, amphetamines, and cocaine were generally reported to have a decrease or no change in patterns of usage in most countries. During the 2008 global financial crisis, drug use patterns were differentially impacted, with expenditures of money for drugs down 2–44%, termed as the “Great Recession” of drug use (19). Although there are preliminary reports suggesting that opioid use is a risk factor for ICU admission in H1N1 infections and a possible risk factor for mortality following COVID-19 infection, rumors about protective effects of opium use in Iran may have led to increased consumption (28, 29). In the US, an already severe opioid overdose crisis worsened since the COVID-19 pandemic, with 30 out of 50 states reporting increases in overdoses between March and June of 2020, with an increase in high potency synthetic opioids such as fentanyl in street supplies and decreased access to harm reduction and OUD treatment services cited as possible drivers of overdose increase (30–32). While concerns have been also raised regarding probable effects of substances on COVID-19 patients (4, 33, 34), more research is needed on changes in drug use patterns and impacts on SUDs.
More than 80% of the countries reported increased use of sedatives and hypnotics. This rise in the demand for sedatives/hypnotics may be related to the stressful situation of the COVID-19 pandemic and its consequences. Survey results also suggest increased use of prescription opioids, perhaps for similar reasons, and changes in services may be needed (35, 36). Canada, Australia, United Kingdom, and Scotland facilitated pharmacy-based methadone-dispensing programs as prescribing opioid-related medications increased (36). This model may help to manage withdrawal syndromes during lockdown-related periods. In the United States, rapid changes in policies provided support to facilitate service delivery for people in opioid treatment programs, such as larger quantities of dispensed methadone and buprenorphine and relaxed regulations around virtual prescriber visits to initiate and continue medications for OUD in order to help patients access and maintain access to medications (35, 37).
The EMCDDA has reported recent increases in the drug demands in European markets (13). The EMCDDA has also noted that due to increases in the retail prices of cannabis and cocaine, the localized supply shortages may exist during the pandemic (12). The UNODC has reported that across all regions globally, many countries have noted a general shortage of different drugs at the retail level, mostly due to reduction in imports or strict lockdown rules, resulting in fewer personal interactions for drug sales (14). The UNODC has also noted a heterogeneous situation on bulk supply, both across drugs and across different countries (14). The UNODC preliminary data were gathered from governmental authorities and open sources (media and UNODC field officers) (14). Our results agree with multiple aspects of these reports of drug supplies.
The UNODC reported that countries with strict rules on social distancing such as the Czech Republic, United Kingdom, Italy, and Iran have been facing increased street drug prices due to lack of availability (14). Other reports from drug-producing countries suggest drug price decrements perhaps as a result of stockpiling of drugs (14). Subsequently, the EMCDDA along with the UNODC have both noted that COVID-19 restrictions have generally led to increases in drug prices, including cocaine, heroin, amphetamines, and cannabis, at the level of street markets (13, 14). Our survey results support these preliminary data reported by the UNODC and EMCDDA.
Respondents mostly reported increases in behavioral addictions during the current pandemic, which may partly confirm the existing concerns on this matter (38, 39). Other small studies suggest increases in addictive behaviors (39–41). Some forms of gambling may have decreased due to financial uncertainties, occupational problems, cessation of sporting events, closure of casinos, and other factors (40, 41). Discussing another addictive behavior, gaming has been represented to be a coping mechanism during the current stressful conditions (42). Accordingly, gaming has increased among college students in India, who use gaming as an antistress mechanism (42). Increased gaming has been occurring globally during the pandemic (43), as well as pornography viewing (44). These and other concerns have led to guidance about Internet use during the pandemic (45).
Advantages and Limitations
ISAM conducted the first global survey in the field of addiction medicine and successfully sampled responses from 77 countries and 177 experts globally. This timely and rapid survey was designed in a multistep fashion including literature review, expert communication, professional qualitative appraisal, and finally a pilot study (17) and was able to rapidly and reliably address urgent gaps in knowledge during the current pandemic. However, there are limitations such as heterogeneity the numbers of respondents from different countries and their disciplines and educational levels. The convenience sample also may impact response rates and other factors. The lack of validated measures is a limitation, as is the lack of options for open-ended responses that would provide a window on the mechanisms driving reported trends. The fact that not all the countries across the world are included in the study may question the nature of the word “global,” which has been used throughout the survey. Given the dynamic nature of pandemics and lack of multicentric epidemiological studies, the survey is a timely approach to provide a snapshot of global clinical addiction medicine concerns during these unprecedented times.
Conclusions and Practical Implications
The objective of the ISAM survey was to provide initial, rapid preliminary evidence about how COVID-19 has affected different situational aspects experienced by people with SUDs globally in order to help reach a better understanding of the current status. Provision of this information to international organizations and regional policymakers should help authorities plan for addressing urgent needs and providing suitable services not only in the current pandemic but also in future similar situations. To properly respond to the emerging demands and situational shifts during the COVID-19 pandemic in the addiction treatment services across the world, at a macro (policy) level, it is critical to recognize the importance of (1) the social safety net and measures used to reduce the social inequality widening gap when such epidemics deteriorate an already vulnerable system, (2) responsive and publicly well-resourced healthcare with adequate supply of appropriate medication, (3) civil liberties, which could help increased participation and a judicious response by law enforcement agencies, and (4) policies that have taken in justifying alcohol sales and cannabis dispensaries as essential services and legislation allowing pharmacists to provide maintenance medications such as benzodiazepines in order to guarantee safe supplies. At a meso (organizational) level, it is important that clinical experience and knowledge on localized drug supply, price, and associated morbidities and mortality is shared within the organization in order to respond adequately. This makes it vital that organizations have a responsive continuity plan that can change with the needs of the population throughout the acute stage of the pandemic. It is also important to establish, support, and sustain varied digital platforms to allow better access to treatment for drug and alcohol using populations and minimize morbidities and possibly mortality. Establishing joint advocacy groups of service users and providers is also critical. At a micro (individual) level, it is important to (1) establish a mechanism for shared decision making through effective communication channels, (2) build the therapeutic environment that welcomes and encourages participation of peer, third sector, and/or frontline workers who are also involved in the care of the individuals in care, (3) support psychologically informed environments and interventions considering stress, uncertainties, isolation, and mental health, and (4) consider providing harm minimization and/or public protection messages and equipment to all in care and others.
In this unique global survey, experts in addiction medicine provided information on changes in regional alcohol and drug availability, price, usage, and related complications. Reported decreases in alcohol and drug supplies appear partly attributable to lockdowns, import/export limitations, and strict regulations. Reduced availability may have generated increases in prices. Reported increases in the use of alcohol, cannabis, prescribed opioids, and sedative/hypnotics may reflect their legal availability (in online markets, drugstores, and dispensaries), while decreased use of amphetamines, cocaine, and opiates may be related to decreased availability due to social distancing, lockdown regulations, and increased prices. Changed drug use patterns may not only impact people with SUDs but also give rise to risky behaviors and related complications. Most issues may potentially be preventable if future lockdown regulations are accompanied by enhanced service provision for at-risk communities.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics Statement
The studies involving human participants were reviewed and approved by the survey protocols and all materials, including the survey questionnaires, received approval from the University of Social Welfare and Rehabilitation Sciences' ethics committee in Tehran, Iran (Code: IR.USWR.REC.1399.061). The participants provided their written informed consent to participate in this study.
International Society of Addiction Medicine—Global Survey Consortium (ISAM-GSC) Members
Adrian Octavian Abagiu1, Franck David Noel Abouna2, Mohamed Hassan Ahmed3, Basma Al-ansari4, Feda Mahmmoud Abu Al-khair5, Mandhar Humaid Almaqbali6, Atul Ambekar7, Sidharth Arya8, Victor Olufolahan Asebikan9, Murad Ali Ayasreh10, Debasish Basu11, Zoubir Benmebarek12, Roshan Bhad7, Mario Blaise13, Nicolas Bonnet14, Jennifer Brasch15, Barbara Broers16, Anja Busse17, Jenna L. Butner18, Moses Camilleri19, Giovanna Campello17, Giuseppe Carra20, Ivan Celic21, Fatemeh Chalabianloo22, Abhishek Chaturvedi23, José de Jesús Eduardo Noyola Cherpitel24, Kelly J. Clark25, Melissa Anne Cyders26, Ernesto de Bernardis27, Abbas Deilamizade28, John Edward Derry29, Naveen Kumar Dhagudu30, Pavla Dolezalova31, Geert Dom32, Adrian John Dunlop33, Mahmoud Mamdouh Elhabiby34, Hussein Elkholy35, Nsidibe Francis Essien36, Ghandi Ilias Farah37, Marica Ferri38, Georgios D Floros39, Catherine Friedman40, Clara Hidalgo Fuderanan41, Gilberto Gerra17, Abhishek Ghosh42, Maka Gogia43, Ilias A. Grammatikopoulos44, Paolo Grandinetti45, Amira Guirguis46, David Gutnisky47, Paul Steven Haber48, Peyman Hassani-Abharian49, Zahra Hooshyari50, Islam Ibrahim Mokhtar Ibrahim34, Hada Fong-ha Ieong51, Regina Nova Indradewi52, Shelly Iskandar53, Thahir Noorul Isra54, Shobhit Jain55, Sandi James56, Seyyed Mohammad hossein Javadi57, Keun Ho Joe58, Darius Jokubonis59, Acka Tushevska Jovanova60, Rama Mohamed Kamal61, Alexander Ivanov Kantchelov62, Preethy Kathiresan7, Gary Katzman63, Paul Kawale64, Audrey Margaret Kern65, Felix Henrique Paim Kessler66, Sung-Gon Sue Kim67, Ann Marie Kimball68, Zeljko Kljucevic69, Kristiana Siste Kurniasanti70, Roneet Lev71, Hae Kook Lee72, Aiste Lengvenyte73, Shaul Lev-ran74, Geni Seseja Mabelya75, Mohamed Ali El Mahi76, J. Maphisa Maphisa77, Icro Maremmani78, Laura Masferrer79, Omid Massah80, Orlagh McCambridge81, Garrett Gregory McGovern82, Aung Kyi Min83, Amir Moghanibashi-Mansourieh57, Jazman Mora-Rios84, Indika Udaya Kumara Mudalige85, Diptadhi Mukherjee86, Pejic Munira Munira87, Bronwyn Myers88, Jayakrishnan Menon T. N.89, Venkata Lakshmi Narasimha90, Nkemakolam Ndionuka91, Ali-Akbar Nejatisafa92, Kamran Niaz17, Asad Tamizuddin Nizami93, Jan H. Nuijens94, Laura Orsolini95, Vantheara Oum96, Adegboyega Adekunle Oyemade97, Irena Rojnia Palavra98, Sagun Ballav Pant99, Joselyn Paredes100, Eric Peyron101, Randall Alberto Quirós102, Rouhollah Qurishi103, Noor ul Zaman Rafiq104, Ranjini Raghavendra Rao105, Woraphat Ratta-apha106, Karren-Lee Raymond107, Jens Reimer108, Eduardo Renaldo109, Tara Rezapour110, James Roy Robertson111, Carlos Roncero112, Fazle Roub113, Elizabeth Jane Rubenstein114, Claudia Ines Rupp115, Elizabeth Saenz17, Mohammad Salehi116, Lampros Samartzis117, Laura Beatriz Sarubbo118, Nusa Segrec119, Bigya Shah120, Hongxian Shen121, Tomohiro Shirasaka122, Steve Shoptaw123, Fransiskus Muronga Sintango124, Veronica Andrea Sosa125, Emilis Subata126, Norberto Sztycberg127, Fatemeh Taghizadeh128, Joseph Brian Tay Wee Teck129, Christian Tjagvad130, Marta Torrens131, Judith Meme Twala132, Ramyadarshni Vadivel133, Joseph Robert Volpicelli134, Jelmer Weijs135, Steven Michael Wintoniw136, Apisak Wittayanookulluk137, Marcin Wojnar138, Sadia Yasir93, Yimenu Yitayih139 and Min Zhao140
1National Institute for Infectious Diseases, Prof. Dr. Matei Bals- Arena OMT Department, Romania
2Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon
3Alamal psychiatric hospital, Dubai, United Arab Emirates
4Sydney Medical School, University of Sydney, NSW, Australia
5Al Ahliyya Amman University, Amman, Jordan
6Ministry of Health, Muscat, Oman
7Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India
8State Drug Dependence Treatment Centre, Institute of Mental Health, Pt BDS University of Health Sciences, India
9Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria
10Addiction Medicine Clinic, Jordan
11Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India
12Addiction Medicine Clinic, Mila, Algeria
13Centre medical Marmottan, France
14Réseau de Prévention des Addictions (RESPADD), France
15Department of Psychiatry and Behavioural Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
16Geneva University Hospitals, Switzerland
17United Nations Office on Drugs and Crime (UNODC), Vienna, Austria
18CUNY School of Medicine, New York, United States
19Agenzija Sedqa, Malta
20Department of Medicine and Surgery, University Milan-Bicocca, Italy
21University Psychiatric Hospital Vrapce - Zagreb, Croatia
22Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway
23Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India
24Addiction Medicine Clinic, Mexico
25Addiction Crisis Solutions, United States
26Department of Psychology, Indiana University Purdue University - Indianapolis, United States
27SerT Lentini, ASP Siracusa, Italy
28Rebirth Charity Society NGO, Tehran, Iran
29Serenity Vista Addiction Treatment Center, Panama.
30Department of Psychiatry, ESIC Medical College, Hyderabad, Telangana, India
31National Institute of Mental Health, Czech Republic
32Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Belgium
33Drug & Alcohol Clinical Services, Hunter New England Local Health District, Australia
34Ain Shams University, Cairo, Egypt
35Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt
36Centre for Research and Information on Substance Abuse, Nigeria
37Addiction Medicine Clinic, Syria
38European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Italy
39Department of Psychiatry, Aristotle University of Thessaloniki, Greece
40Brown University and Lifespan Health System, Providence, Rhode Island, United States
41Fuderanan Mental Health Clinic, Philippines
42Drug De-addiction & Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India
43Georgian Harm Reduction Network, Georgia
44Organization Against Drugs, Primary Care Health Center, Veria, Greece
45Addictions Services (Ser.D.), Department of Territorial Services, ASL Teramo, Italy
46Swansea University Medical School, Institute of Life Sciences 2, Singleton Campus, SA2 8PP, Wales, United Kingdom
47Universidad de Buenos Aires, Argentina
48University of Sydney, Australia
49Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran
50Tehran University of Medical Sciences, Tehran, Iran
51Department of Anesthesiology, Yale University, United States
52Drugs Rehabilitation Center, National Narcotics Board of Indonesia, Indonesia
53Department of Psychiatry, Universitas Padjadjaran, Bandung, West Java, Indonesia
54National Institute of Education, Sri Lanka
55Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India
56Univeristi Malaysia Sabah, Malaysia
57Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran
58National Center for Mental Health of Korea, South Korea
59Republican Center for Addictive Disorders, Lithuania
60Addiction Medicine Clinic, North Macedonia
61Naufar Institute, Doha, Qatar
62The Kantchelov Clinic, Sofia, Bulgaria
63Mount Sinai Medical Center, New York, United States
64African Institute for Development Policy, Malawi
65Sobriety Centers of New Hampshire, United States
66Federal University of Rio Grande do Sul, Brazil
67Pusan National University Yangsan Hospital, Department of Neuropsychiatry, Yangsan South Korea
68Chatham House, United States
69Institute for Public Health of Split-Dalmatia County, Croatia
70Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Indonesia
71Scripps Mercy Hospital, San Diego, United States
72Department of Psychiatry, The Catholic University of Korea, Seoul, Korea
73Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania
74Israel Center on Addiction, Netanya, Israel
75Community Health Work, Tanzania
76Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan
77University of Botswana, Botswana
78V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy
79CAS Girona, Department of Psychology, University of Girona, Spain
80Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
81Community addiction team, Southern Health and Social Care Trust, Northern Ireland, United Kingdom
82Priority Medical Clinic, Dublin, Ireland
83Save the Children International Organization, Burma
84Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México
85Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defence University, Sri Lanka
86Centre for Addiction Medicine, NIMHANS, Bangalore, India
87Kleopatra Kodric, Irena Nisic, Slovenia
88Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa
89NIMHANS, Bangalore, India
90Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India
91Federal Neuropsychiatric Hospital, Calabar, Nigeria
92Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran
93Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan
94Brijder Addiction Care, Zaandam, Netherlands
95Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy
96Koh Kong Provincial Hospital, Cambodia.
97Kaiser Permanente, United States
98Psychiatric hospital Sveti Ivan, Zagreb, Croatia
99Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Nepal
100Universidad de El Salvador, El Salvador
101AddiPsy, Lyon, France
102Addiction Medicine Clinic, Costa Rica
103Novadic-Kentron Addiction Care Network, Vught, Netherlands
104Phoenix Foundation for Research and Development, Pakistan
105Barwon Health, Geelong, Australia
106Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
107University of the Sunshine Coast (USC), Queensland, Australia
108Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
109Drugs Rehabilitation Center, National Narcotics Board of Indonesia
110Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran
111Usher Institute, University of Edinburgh, United Kingdom
112Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain
113PGIMER, Chandigarh, India
114Street Health Centre, Canada
115Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck Austria
116Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
117Medical School, University of Cyprus, Cyprus
118Clínica Psiquiátrica de la Facultad de Medicina, Uruguay
119Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia
120Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal
121Department of Psychiatry, Second Xiangya Hospital, Central South University, China
122Department of Psychiatry, Teine Keijinkai Medical Center, Japan
123David Geffen School of Medicine at UCLA, Department of Family Medicine, United States
124Health Professions Councils of Namibia, Namibia
125Addiction Medicine Clinic, Uruguay
126Republican Center for Addictive Disorders, Lithuania
127Asociasion Programa Andres Argentina, Argentina
128Mazandaran University of Medical Sciences, Mazandaran, Iran
129MRC/CSO SPHSU, University of Glasgow, United Kingdom
130Gladsaxe Substance Use Disorder Treatment Centre, Denmark
131Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research Barcelona, Spain
132NACADA, Kenya
133Waikato District Health Board (WDHB) Hamilton, New Zealand
134Institute of Addiction Medicine, United States
135Jellinek, Amsterdam, Netherlands
136Addictions Foundation of Manitoba, Canada
137Thanyarak Chiangmai Hospital, Thailand
138Medical University of Warsaw, Warsaw, Poland
139Jimma University, Ethiopia
140Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.646206/full#supplementary-material